Camp4 wins Australian clearance for Phase 1/2 CMP-002 trial in SYNGAP1-related disorderPUBT·13 hours agoCAMP+8.23%
CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related DisorderUnusual Whales·13 hours agoCAMP+8.23%
12 Health Care Stocks Moving In Wednesday's After-Market Sessionbenzinga_article·Jul 22 at 04:05 PMZYBT-11.56%CYH-0.37%
12 Health Care Stocks Moving In Monday's Pre-Market Sessionbenzinga_article·Jul 20 at 07:05 AMBRNS-0.17%VBIO-4.81%
We Think Camp4 Therapeutics (NASDAQ:CAMP) Can Afford To Drive Business GrowthSimplywall·Jul 18 at 08:05 AMCAMP+8.23%
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire·Jul 17 at 03:05 PMCAMP+8.23%
X4 Pharmaceuticals appoints CAMP4 CFO Kelly Gold to board, audit committeePUBT·Jul 1 at 06:01 AMXFOR+2.34%CAMP+8.23%
Positive Report for CAMP4 Therapeutics Corporation (CAMP) from J.P. MorganTip Ranks·Jun 23 at 07:37 AMCAMP+8.23%
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Unusual Whales·Jun 21 at 05:44 PMCAMP+8.23%
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CAMP Stock NewsStockTitan·Jun 19 at 07:05 AMCAMP+8.23%
This Exxon Mobil Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesdaybenzinga_article·Jun 16 at 07:01 AMCAMP+8.23%XOM-1.38%
